Skip to content
WorldBrand.AI

Huahai Pharmaceutical

Controversies

Controversies tied to this brand in public sources. A listing is not a finding of fault.

Back to profile1 entries

  1. 2018

    NDMA impurity detected in valsartan API, triggering global recalls and import restrictions

    In 2018, NDMA was detected in valsartan active pharmaceutical ingredient (API) produced by Huahai Pharmaceutical. Multiple countries initiated recalls of affected medicines, and questions were raised about the timing of disclosure and recalls in China. The company halted production and described its risk assessment and communications with regulators; the United States and Europe subsequently imposed restrictions on products linked to its Chuannan production site. The incident was confined to the affected API and facility.

    Source